AMD: Treatment Options and Availability of Lucentis in Taiwan - Ophthalmology

More Info

---

Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, particularly those over the age of 50. It affects the macula, the part of the retina responsible for central vision, which is crucial for tasks such as reading, driving, and recognizing faces. AMD can be classified into two main types: dry AMD and wet AMD. The latter is characterized by the growth of abnormal blood vessels under the retina, which can leak fluid and lead to rapid vision loss.

One of the most effective treatments for wet AMD is a medication called Lucentis (ranibizumab). Lucentis is an anti-VEGF (vascular endothelial growth factor) therapy that works by inhibiting the growth of these abnormal blood vessels, thereby reducing fluid leakage and helping to stabilize or improve vision. Clinical studies have shown that Lucentis can significantly improve visual acuity in patients with wet AMD when administered through intravitreal injections.

In Taiwan, Lucentis is indeed available for patients suffering from wet AMD. The Taiwanese healthcare system recognizes the importance of this treatment, and it is included in the National Health Insurance (NHI) coverage for eligible patients. This means that if your mother qualifies for treatment, her medical expenses related to Lucentis injections may be partially or fully covered by the NHI, depending on her specific circumstances and the healthcare provider's recommendations.

For your mother, who is 93 years old and experiencing declining vision due to AMD, it is crucial to consult with an ophthalmologist who specializes in retinal diseases. The doctor will conduct a thorough examination, which may include optical coherence tomography (OCT) and fluorescein angiography, to assess the extent of her condition and determine the most appropriate treatment plan. If wet AMD is confirmed, the ophthalmologist may recommend starting Lucentis injections as soon as possible to help preserve her vision.

In addition to Lucentis, there are other treatment options available for AMD, including photodynamic therapy and other anti-VEGF agents like Eylea (aflibercept) and Beovu (brolucizumab). The choice of treatment will depend on various factors, including the specific characteristics of the AMD, the patient's overall health, and their response to previous treatments.

It's also important to consider lifestyle modifications that can support eye health, such as maintaining a balanced diet rich in antioxidants (like leafy greens and fish), quitting smoking, and managing cardiovascular health. Regular follow-up appointments with the ophthalmologist are essential to monitor the progression of the disease and adjust treatment as necessary.

In summary, Lucentis is available in Taiwan and is a viable treatment option for wet AMD. Given your mother's age and the progression of her vision loss, it is advisable to seek medical attention promptly to explore this treatment option and discuss any other potential therapies that may be beneficial for her condition.